to view your mail
Yahoo Finance Plus
U.S. Markets closed
Pacific Biosciences of California, Inc. (PACB)
NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
At close: 4:00PM EDT
5,152 reactions on $PACB conversation
Sign in to post a message.
Let’s FINALLY break $30 again today!
Our latest blog looks at how Sequel - our new DNA sequencing system - will help us improve our matching process & save more lives.
A big thank you to
for their generous grant which made this purchase possible.
They got 8 Sequencers:
Novogene are a real global force in sequencing services and it's great to see that they're also broadening their technology base with a significant investment in
· Jun 14
1.2 million samples and counting! How Novogene, an #NGS services provider for #scientific research institutes, expanded around the globe in one exciting decade.
This quarter sales for PACB seems like an inflection point. They have to show that hiring of new sales positions is yielding results. Their trajectory may mimic TXG. Long term perspective is still strong
9 more installed in Europe:
#8 - @NovogeneAMEA
Novogene is a leading provider of genomic services and solutions in Next Generation Sequencing.
We are a science-based company, specializing in molecular diagnostics for transplantation and personalized health care.
Here is the statement from Richard Shippy upon his appointment as chief business officer at bingo today. See if you can spot the lie:
“I am extremely enthusiastic about becoming a part of Bionano. I’m grateful to Erik and the Bionano board for this unique opportunity,” commented Rich Shippy, CBO of Bionano Genomics. “I’ve believed my entire career that genome structure and SVs are the drivers of biology and pathology in ways that are far more significant than single-nucleotide variants. What has limited our ability in research and medicine to harness and exploit SVs has been the technology to detect them. Arrays are limited in the scope of SVs they can detect. Sequencing, even long-read sequencing, is not able to address SVs either. I believe OGM has the potential to transform our understanding of SVs and the way in which they are analyzed in the clinic by providing a better solution that is substantially more efficient to use, which can in turn improve patients’ lives.”
Biomimetics, I haven’t bailed out at all, in fact I haven’t sold a single share. I am a surgeon, we hadn’t been doing elective cases due to Pandemic , now things are doubly busy. I have not been on board till today. I have been checking price off and on. I believe Pacbio has great future. If I ever sell I will let you all know. Best of luck everyone.
All that selling and buying based on what Fed is going to do?
Fed holds rates at near zero, projects two possible rate hikes by end of 2023
Wed, June 16, 2021, 2:00 PM
O/T: Anybody looking into CRISPR Tech:
Crispr wades into SCD (sickle cell disease) and into BTD (beta Thalessemia):
Editing from HbS to HbF ( BEAM looking at HbS to HbG -Makassar Editing)
#1: Vertex and CRISPR Therapeutics Present New Data in 22 Patients With Greater Than 3 Months Follow-Up Post-Treatment With Investigational CRISPR/Cas9 Gene-Editing Therapy, CTX001™ at European Hematology Association Annual Meeting
- Beta thalassemia: All 15 patients were transfusion independent after CTX001 infusion -
- Sickle cell disease: All seven patients were free of vaso-occlusive crises after CTX001 infusion -
#2: PRESS RELEASEEditas Medicine Presents Preclinical Data Supporting The Initiation Of The EDIT-301 Phase 1/2 RUBY Clinical Trial For The Treatment Of Sickle Cell Disease At The European Hematology Association CongressJune 11, 2021 at 6:00 AM EDT
Preclinical data demonstrated robust fetal hemoglobin (HbF) induction in erythroid progeny cells with no detection of off-target editing; cells showed reduced sickling and improved rheological behavior
RUBY trial of EDIT-301 for sickle cell disease active and recruiting
dear handfull of posting active PacB longs, I am not in since a long time, just 3 months or so , but somehow just being drawn to that stock.
I really appreciate this forum, being sincere. I am from a very different profession, no biology and chemistry, but intellect and gut feeling. Hence I am in; and even though i don`t understand some of your comments about sequencing, i read and appreciate. makes me feel better about sticking to it :)- thanks
My next jackpot in investing - not gloating but sharing with the best MB I know:
Anavex Life Sciences Corp. (AVXL)
NasdaqCM - NasdaqCM Real Time Price. Currency in USD
As of 2:40PM EDT. Market open.
Whoa. Poached another ILMN employee.
At this rate, the ILMN staff are going to be part of the PACB management. They couldn't buy PACB, so let's join them instead!
Definitely the right sort of new hire. They must be giving him some impressive stock plan to come over.
But that's what the North Star investment was earmarked for, amongst other things
PacBio continues to build out their infrastructure setting the stage for becoming the dominant player in their space for years to come. Very smart move.
PACB is simply too inadequate--too much it cannot detect, esp. in the SV area--to make in the very competitive playing field of the future. There is little need for PACB in the long-read area because Bionano can do it all. And Illumina is and will remain king of short read sequencing. It looks like PACB is about to be left out to dry.
Last earnings call, Christian Henry: "And then also, the other side of horizontal, of course, is, are there informatics opportunities? You know, in the past, we've been very successful at integrating informatic-type opportunities to, kind of round out the product portfolio. And there's adjacencies, and that we're looking very carefully at, are there -- you know, our objective is to be the world's most advanced, you know, solutions company for biology. Like that's really where we're going, way beyond just long-read sequencing. And I think there are opportunities out there in the market."
Pacific Biosciences of California, Inc. ( PACB ￼Loading...) , a leading provider of high-quality, long-read sequencing platforms, today welcomed Neil Ward to the new role of Vice President and General Manager for the company’s Europe, Middle East, and Africa (EMEA) region to expand and develop the team and infrastructure to capitalize on the immense potential for genomics in this area of the world.
Neil is a genomics industry veteran with more than two decades of global experience. He most recently served as Senior Sales Director for Northern Europe at Illumina. In his various commercial roles, Neil has served as a key contributor in many of the world’s largest genomics projects including Genomics England’s 100,000 Genome Project, the Estonian Genome Project, and the whole genome sequencing of the 500,000 UK Biobank samples. Prior to his 13 years at Illumina, Neil held bioinformatics and sales roles at leading institutions, including Agilent, Silicon Genetics, Oxford Biomedica and Celltech.
10 minute assembly geared for Pacbio HiFi reads.
A 10-minute #genome assembly you say? That seems like a record—looking forward to reading more about this method, but if Andrew finds it interesting—it’s absolutely worth the deep-dive.
This looks really interesting. The associated GitHub is here:
It indicates assembly of a human genome in 10 minutes with 8 cores. I'm looking forward to give it a shot. I like the idea.
How do make efficient better? IDK
We propose a very efficient variant of de Bruijn graphs, specifically geared towards assembly of long and accurate reads (PacBio HiFi).
12:49 PM · Jun 10, 2021·Twitter Web App
mdBGs can assemble whole human genome HiFi data (HG002) with high contiguity in 10 minutes, using 10GB on a single computer with 8 cores.
U.S. software mogul John McAfee dies by hanging in Spanish prison, lawyer says
'We’ve got to remove the anchor of this debt': Fmr. Secretary of Education John King on student loan forgiveness
Yahoo Finance Video
Brooke Shields swimsuit Instagram photo with daughters sends American Eagle stock flying
Advertise with us
© 2021 Verizon Media. All rights reserved.
About Our Ads
Discover new investment ideas by accessing unbiased, in-depth investment research